1. p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome
- Author
-
Joaquina Maurício, Rui Henrique, Mariana Cantante, Carmen Jerónimo, Paula Lopes, Maria Ana Alzamora, João Lobo, Isaac Braga, and Rita Guimarães
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Prognostic variable ,Urology ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Testicular Neoplasms ,Internal medicine ,Biomarkers, Tumor ,Medicine ,Humans ,neoplasms ,Retrospective Studies ,Cisplatin ,Chemotherapy ,030219 obstetrics & reproductive medicine ,biology ,business.industry ,Proto-Oncogene Proteins c-mdm2 ,Neoplasms, Germ Cell and Embryonal ,medicine.disease ,Prognosis ,Primary tumor ,Testicular germ cell ,Reproductive Medicine ,Drug Resistance, Neoplasm ,Cohort ,biology.protein ,Mdm2 ,Tumor Suppressor Protein p53 ,business ,medicine.drug ,Biomedical sciences - Abstract
BACKGROUND Testicular germ cell tumors (TGCTs) are highly sensitive to platinum-based chemotherapy, and wild-type p53 seems to play a pivotal role in this susceptibility. On the other hand, overexpression of MDM2 seems to entail treatment resistance and unfavorable prognosis. OBJECTIVES We aimed to describe p53 and MDM2 immunoexpression in a well-characterized cohort of primary and metastatic TGCTs and evaluate associations with clinicopathological and prognostic variables, including survival. MATERIALS AND METHODS 237 primary tumor samples and 12 metastases were evaluated for p53 and MDM2 immunoexpression using digital image analysis. Clinical records of all patients were reviewed for baseline clinical/pathologic characteristics and follow-up. RESULTS A significant positive correlation between p53 and MDM2 H-scores was found (rs = 0.590, P
- Published
- 2020